Clinical trialNCT05797168RecruitingPhase 1/PHASE2Interventional

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

SponsorAstraZenecaEnrollment602Endometrial CancerLung AdenocarcinomaLung Squamous Cell CarcinomaOvarian Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This research is designed to determine if experimental treatment with Antibody-drug conjugate, AZD5335, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced tumors

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Funda Meric-Bernstam, MD
UT MD Anderson Cancer Center
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

60 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia

Research Site
Liverpool, Australia
Recruiting
Research Site
Melbourne, Australia
Recruiting

Canada

Research Site
Edmonton, Alberta, Canada
Recruiting
Research Site
London, Ontario, Canada
Recruiting
Research Site
Toronto, Ontario, Canada
Recruiting
Research Site
Montreal, Quebec, Canada
Recruiting
Research Site
Montreal, Quebec, Canada
Recruiting

China

Research Site
Chengdu, China
Recruiting
Research Site
Chongqing, China
Recruiting
Research Site
Guangzhou, China
Recruiting
Research Site
Guangzhou, China
Recruiting
Research Site
Jinan, China
Recruiting
Research Site
Xi'an, China
Recruiting
Research Site
Zhengzhou, China
Recruiting

Germany

Research Site
Berlin, Germany
Recruiting
Research Site
Essen, Germany
Not, yet, recruiting
Research Site
Freiburg im Breisgau, Germany
Recruiting
Research Site
Hanover, Germany
Recruiting
Research Site
Leipzig, Germany
Recruiting
Research Site
Mannheim, Germany
Recruiting
Research Site
Regensburg, Germany
Recruiting

Israel

Research Site
Haifa, Israel
Recruiting
Research Site
Ramat Gan, Israel
Recruiting

Japan

Research Site
Hidaka-shi, Japan
Recruiting
Research Site
Kashiwa, Japan
Recruiting
Research Site
Kōtoku, Japan
Recruiting
Research Site
Sunto-gun, Japan
Recruiting
Research Site
Tokyo, Japan
Recruiting

South Korea

Research Site
Seoul, South Korea
Recruiting
Research Site
Seoul, South Korea
Recruiting

Spain

Research Site
Barcelona, Spain
Recruiting
Research Site
Madrid, Spain
Recruiting
Research Site
Madrid, Spain
Recruiting
Research Site
Málaga, Spain
Recruiting

Taiwan

Research Site
Taichung, Taiwan
Recruiting
Research Site
Tainan, Taiwan
Recruiting
Research Site
Taipei, Taiwan
Recruiting
Research Site
Taipei, Taiwan
Recruiting

Turkey (Türkiye)

Research Site
Ankara, Turkey (Türkiye)
Recruiting
Research Site
Ankara, Turkey (Türkiye)
Recruiting

20 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Bevacizumab →Carboplatin →Azd9574Pembrolizumab →SaruparibTorvutatug samrotecan

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 5 Jun 2023
Primary completion: 4 Aug 2028
Completion: 4 Aug 2028
Last update posted: 21 Aug 2026
Registered enrollment: 602
Registry id: NCT05797168

Cross-registrations

EU-CTR / CTIS (EudraCT)2022-502576-23-00

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.